SCHEMBL403263

SCHEMBL403263

CCOc1ccccc1Cc1nc2cc(C(=O)O)ccc2c(=O)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.57
KDM4E B2RXH2 5/20 0.57
RECQL P46063 1/20 0.57
PDE5A O76074 1/20 0.56
TP53 P04637 2/20 0.48
G6PD P11413 1/20 0.48
GUSB P08236 2/20 0.47
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
TNKS2 Q9H2K2 1/20 0.43
KMT2A Q03164 2/20 0.43
MGLL Q99685 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.42
ATM Q13315 1/20 0.42
ALOX15 P16050 2/20 0.41
MAPK1 P28482 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405782 0.89 POLB (0.59) POLBKDM4ERECQLPDE5AMAPT
SCHEMBL404893 0.84 PDE5A (0.64) POLBKDM4ERECQLPDE5AMAPT
SCHEMBL404827 0.82 PDE5A (0.58) POLBKDM4ERECQLPDE5AMAPT
SCHEMBL17900820 0.82 KDM4E (0.64) POLBKDM4ERECQLPDE5AMAPT
SCHEMBL398946 0.82 POLB (0.52) POLBKDM4ERECQLPDE5AMAPT
SCHEMBL406054 0.81 KDM4E (0.62) POLBKDM4ERECQLPDE5AMAPT
SCHEMBL403044 0.81 KDM4E (0.62) POLBKDM4ERECQLPDE5AMAPT
SCHEMBL401367 0.81 KDM4E (0.71) POLBKDM4ERECQLPDE5AMAPT
SCHEMBL400992 0.81 PDE5A (0.61) POLBKDM4ERECQLPDE5ATP53
SCHEMBL403714 0.80 PDE5A (0.69) POLBKDM4ERECQLPDE5ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050739-B1 QUINAZOLINE DERIVATIVE ASKA PHARM CO LTD (JP) 2016-07-06 EP disclosed
CN-101501007-B Quinazoline derivative ASKA PARMACEUTICAL CO LTD 2014-01-29 CN disclosed
US-8101624-B2 Quinazoline derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-24 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20090318478-A1 QUINAZOLINE DERIVATIVES ASKA PHARMACEUTICAL CO., LTD. 2009-12-24 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
CN-101557826-A Therapeutic agent for urinary tract disease ASKA PHARM CO LTD (JP) 2009-10-14 CN disclosed
CN-101501007-A Quinazoline derivative ASKA PARMACEUTICAL CO LTD (JP) 2009-08-05 CN disclosed
EP-2050739-A1 QUINAZOLINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD POLB 555/4885KDM4E 4291/4885RECQL 878/4885
US-20090318478-A1 QUINAZOLINE DERIVATIVES PDE9A, PDE3A, PDE5A POLB 1464/4885KDM4E 2869/4885RECQL 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.